August 2010 in “Oncology Times” Provenge extends prostate cancer survival by about 4 months.
June 2010 in “Journal of Chemical Crystallography” The compound was successfully made and shows potential for treating prostate cancer.
February 2010 in “Journal of The American Academy of Dermatology” Methotrexate treatment for rheumatoid arthritis has a serious infection rate of about two per 100 patient-years.
January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
September 2009 in “European Urology Supplements” After prostate removal surgery, higher initial prostate size was linked to higher urethral PSA levels and more severe male pattern baldness.
March 2009 in “The Journal of Urology” Shorter PSADT after prostate surgery is linked to higher risk of death.
March 2009 in “The Journal of Urology” Low dose finasteride causes only small changes in PSA levels in older men with BPH.
March 2009 in “The Journal of Urology” Finasteride improves urinary symptoms and quality of life in BPH patients, especially with larger prostate size.
January 2009 in “Journal of Jilin Medical College” SDG helps reduce BPH effects in rats.
May 2007 in “The Journal of Urology” Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.
October 2006 in “Urology” Combination therapy with Finasteride is more effective than alpha-blocker alone for BPH symptoms in small prostate volume.
October 2006 in “Urology” The document aimed to understand how certain treatments affect blood vessel growth in rat prostates.
September 2004 in “Urology” Finasteride may reduce prostate cancer risk.
January 2004 in “Anticancer Research” Long-term antiandrogen use may increase aggressive prostate cancer risk.
April 2003 in “Experimental Dermatology” The workshop highlighted the genetic links and psychological impacts of hair loss and skin disorders.
February 2003 in “European Urology Supplements” Baseline PSA levels affect general health and sexual satisfaction in men with BPH treated with finasteride or placebo.
December 1998 in “Acta Crystallographica Section C-crystal Structure Communications” A new compound with strong antiandrogenic effects was found, potentially useful for treating conditions like acne and prostate cancer.
January 2022 in “Springer eBooks” The book explains causes and treatments for common hair loss, its psychological effects, related health risks, and emphasizes early screening and lifestyle changes.
December 2019 in “Reactions Weekly” Man stopped medications due to sexual side effects, found relief with prostatic artery embolisation.
March 2023 in “The Journal of Urology” Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
May 2022 in “Current Enzyme Inhibition” Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.
January 2018 in “日本薬理学会年会要旨集 =” Stopping finasteride improves sperm quality but not semen volume in young men.
October 2015 in “Elsevier eBooks” Finasteride helps hair growth and prostate issues but may cause sexual side effects and increase tumor risk.
March 2015 in “The Journal of Urology” Finasteride reduces PSA levels by around 40-50% in BPH patients.
9 citations
,
June 2018 in “Scientific Reports” People with certain types of alopecia have a slightly higher risk of cancer, especially thyroid, bladder, and prostate cancers.
309 citations
,
June 2001 in “Molecular and Cellular Endocrinology” Mutations in the androgen receptor gene cause androgen insensitivity, leading to female traits in genetically male individuals.
280 citations
,
May 2005 in “Andrology” Testosterone treatment for older men can have short-term benefits, but long-term risks are unclear, requiring careful evaluation and monitoring.
129 citations
,
February 2006 in “Andrology” Men with low testosterone should be carefully evaluated and monitored before and during treatment.
121 citations
,
November 2020 in “Endocrine” Male hormones like testosterone may make COVID-19 worse, and testing for sensitivity to these hormones could help predict how severe a patient's symptoms might be. Treatments that reduce these hormones are being explored.
101 citations
,
October 2007 in “Journal of Biological Chemistry” Reduced matriptase activity causes skin and hair issues in both humans and mice.